Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06009237 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06009237 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 24 participants.
The verdict
NCT06009237, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability of ABBV-903 or placebo in healthy adult Japanese and Han Chinese subjects.
Interventions
- DRUG ABBV-903
- DRUG Placebo for ABBV-903
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2023-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06009237
The ClinicalTrials.gov registry entry for NCT06009237 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-903 is the first listed.
NCT06009237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06009237 about?
NCT06009237 is a clinical study titled "A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants". The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability of ABBV-903 or placebo in healthy adult Japanese and Han Chinese subjects.
What is the current status of trial NCT06009237?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-08-23. Estimated completion is 2023-10-30.
What interventions are being tested in trial NCT06009237?
The interventions under investigation include: ABBV-903 (DRUG), Placebo for ABBV-903 (DRUG).
Who is sponsoring clinical trial NCT06009237?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.